33,320 results match your criteria Lymphoma Bone


Association of ionizing radiation dose from common medical diagnostic procedures and lymphoma risk in the Epilymph case-control study.

PLoS One 2020 10;15(7):e0235658. Epub 2020 Jul 10.

CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Medical diagnostic X-rays are an important source of ionizing radiation (IR) exposure in the general population; however, it is unclear if the resulting low patient doses increase lymphoma risk. We examined the association between lifetime medical diagnostic X-ray dose and lymphoma risk, taking into account potential confounding factors, including medical history. The international Epilymph study (conducted in the Czech-Republic, France, Germany, Ireland, Italy, and Spain) collected self-reported information on common diagnostic X-ray procedures from 2,362 lymphoma cases and 2,465 frequency-matched (age, sex, country) controls. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235658PLOS

Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.

Br J Haematol 2020 Jul 9. Epub 2020 Jul 9.

Department of Children and Adolescents Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.

Relapses involving the central nervous system (CNS) are rare in children and adolescents with ALK+ anaplastic large cell lymphoma (ALCL) treated with regimens including CNS prophylaxis. Early identification of patients at high-risk for CNS relapse would enable stratification and better adaptation of initial treatment especially in the light of the upcoming targeted therapies with limited CNS penetration. We analyzed clinical and histological data of all ALK+ALCL patients with CNS relapse registered in ALCL99-database with the aim to describe risk factors and outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.16755DOI Listing

Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.

J Int Med Res 2020 Jul;48(7):300060520936053

Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Primary bone marrow diffuse large B cell lymphoma (DLBCL) is an independent pathologic type with a poor prognosis when treated with standard chemoimmunotherapy. Generally, rituximab-based high-dose chemotherapy regimens such as dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) can be administered to young patients, followed by autologous stem cell transplantation. For elderly patients, the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) regimen is well tolerated, but it is an insufficient induction therapy for this group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300060520936053DOI Listing

Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.

Leuk Lymphoma 2020 Jul 9:1-7. Epub 2020 Jul 9.

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Progression of disease within 24 months of initial therapy (POD24) has previously been identified as a predictor of reduced overall survival (OS) for patients with follicular lymphoma (FL). Here we attempt to validate this finding in a retrospective cohort and understand whether the method by which progression is determined, clinically or radiographically, influences POD24 robustness. We reviewed records of 635 patients with FL and included 317 patients in our analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786554DOI Listing

Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.

Leuk Lymphoma 2020 Jul 9:1-7. Epub 2020 Jul 9.

Hematology and Bone Marrow Transplantation, Yale University School of Medicine, New Haven, CT, USA.

We report results on 23 patients with cutaneous T cell lymphoma (7 primary cutaneous γδ T cell lymphoma [PCGDT], 16 mycosis fungoides/Sézary syndrome [MF/SS]) who underwent allogeneic stem cell transplantation. All pts had skin involvement, 14 had total skin electron beam before conditioning. Donors were 10/10 HLA matched related (13), 5/10 haploidentical (4), and matched unrelated (5) or mismatched unrelated (1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1790555DOI Listing

Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma.

PLoS One 2020 8;15(7):e0235786. Epub 2020 Jul 8.

Department of Internal Medicine IV, Haematology and Oncology, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany.

In front-line treatment of diffuse large B-cell lymphoma (DLBCL), prior studies suggest that concordant but not discordant involvement of the bone marrow (BM) portends a poor prognosis. The prognostic impact of bone marrow infiltration (BMI) in recurrent or refractory DLBCL (r/rDLBCL) and transformed indolent lymphoma (r/rTRIL) patients is less clear. Thus, we examined the prognostic significance of the infiltration of bone marrow (BMI) by concordant, large B-cells (conBMI) and discordant, small B-cells (disBMI) in this patient group. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235786PLOS

Solitary long-bone epiphyseal lesions in children: radiologic-pathological correlation and epidemiology.

Pediatr Radiol 2020 Jul 7. Epub 2020 Jul 7.

Department of Pediatric Radiology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd., Philadelphia, PA, 19104, USA.

Background: Solitary epiphyseal lesions are rare and present with nonspecific imaging features. Knowledge regarding etiologies of pediatric epiphyseal lesions is limited to small studies.

Objective: The purpose of this study was to determine the relative incidence of pathologies affecting the pediatric epiphysis based on biopsy-proven cases with imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00247-020-04752-8DOI Listing

Retrospective Analysis of the Treatment Outcome in Myeloid Leukemia of Down Syndrome in Polish Pediatric Leukemia and Lymphoma Study Group From 2005 to 2019.

Front Pediatr 2020 19;8:277. Epub 2020 Jun 19.

Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland.

Children with Down syndrome (DS) have increased risk of myeloid leukemia (ML), but specific treatment protocols ensure excellent outcome. This study was a retrospective analysis of the treatment results and genetic characteristics of ML of DS (ML-DS) in Poland from 2005 to 2019. All 54 patients with ML-DS registered in the Polish Pediatric Leukemia and Lymphoma Study Group in analyzed period were enrolled to the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2020.00277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317010PMC

Small lymphocytic lymphoma in true trilineage hematopoietic tissue within heterotopic ossification in an enucleated blind painful eye: a case report.

J Med Case Rep 2020 Jul 8;14(1):92. Epub 2020 Jul 8.

Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele - Milan, Italy.

Background: The finding of hematological malignancies within bone marrow in heterotopic ossification has been reported only a handful of times previously in the literature. We described a case of true trilineage hematopoiesis in an excised area of heterotopic ossification from an enucleated blind painful eye.

Case Presentation: A 70-year-old Caucasian man, positive for asymptomatic lymphoplasmacytic lymphoma, presented with a blind painful right eye in our ophthalmology department to evaluate enucleation bulbi. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-020-02430-9DOI Listing

Incidence, prevalence, and outcomes of systemic malignancy with bone metastases.

J Orthop Surg (Hong Kong) 2020 Jan-Apr;28(2):2309499020915989

Department of Orthopedic Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China.

Purpose: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database.

Methods: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2309499020915989DOI Listing

Forkhead Box C1 (FOXC1) Expression in Stromal Cells within the Microenvironment of T and NK Cell Lymphomas: Association with Tumor Dormancy and Activation.

Cancer Res Treat 2020 Jul 3. Epub 2020 Jul 3.

Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.

Purpose: Forkhead box C1 (FOXC1) is critical for maintaining bone marrow microenvironments during hematopoiesis, but its role in hematological malignancies remains obscure. Here, we investigated whether FOXC1 regulates tumor dormancy and activation in the microenvironments of T and natural killer (NK) cell lymphomas.

Materials And Methods: One hundred and twenty cases of T and NK cell lymphomas were included; the immunohistochemical expression of FOXC1 was investigated in stromal cells, and numbers of FOXC1+ stromal cells were counted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.032DOI Listing

Proline‑rich polypeptide‑1 decreases cancer stem cell population by targeting BAFF chromatin‑remodeling complexes in human chondrosarcoma JJ012 cells.

Oncol Rep 2020 Jul 14;44(1):393-403. Epub 2020 May 14.

Department of Orthopaedics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA.

Chondrosarcoma is the second most common primary malignant bone tumor and is resistant to chemotherapy and radiation. Inadequate treatment response and poor prognosis requires novel therapeutic approaches. Proline‑rich polypeptide‑1 (PRP‑1), synthesized by brain neurosecretory cells, has demonstrated antitumor properties in JJ012‑cells; however, its underlying molecular mechanism remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2020.7612DOI Listing

Cladribine Induces ATF4 Mediated Apoptosis and Synergizes with SAHA in Diffuse Large B-Cell Lymphoma Cells.

Int J Med Sci 2020 30;17(10):1375-1384. Epub 2020 May 30.

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. In the present study, we demonstrated that cladribine inhibited cell proliferation and induced G phase arrest in human DLBCL cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/ijms.41793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330656PMC

Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias.

Acta Histochem Cytochem 2020 Jun 29;53(3):43-53. Epub 2020 Apr 29.

Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.

Leukemias are refractory hematopoietic malignancies, for which the development of new therapeutic agents requires studies using tumor-bearing mouse models. Although several organs are commonly examined in such studies to evaluate the disease course, the effectiveness of interventions and the localization of tumor cells in the affected organs are still unclear. In this study, we histologically examined the distribution of leukemia cells in several organs using two leukemic mouse models produced by the administration of two cell lines (THP-1, a human myelomonocytic leukemia, and A20, a mouse B cell leukemia/lymphoma) to severe immunodeficient mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1267/ahc.19035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322163PMC

Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.

Clin Lymphoma Myeloma Leuk 2020 Jun 11. Epub 2020 Jun 11.

Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Background: Lenalidomide and ixazomib maintenance improve long-term outcomes in newly diagnosed multiple myeloma (NDMM) patients. However, there is less evidence to support bortezomib (BTZ) maintenance therapy, and real-life data on maintenance are scarce. We investigated the efficacy and safety of BTZ maintenance therapy in NDMM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.06.002DOI Listing

Primary refractory multiple myeloma: a real-world experience with 85 cases.

Leuk Lymphoma 2020 Jul 5:1-8. Epub 2020 Jul 5.

School of Medicine, Emory University, Atlanta, GA, USA.

This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1788014DOI Listing

Management of newly diagnosed transplant ineligible multiple myeloma.

Leuk Lymphoma 2020 Jul 4:1-12. Epub 2020 Jul 4.

Department of Hematologic Oncology & Blood Disorders, Division of Plasma Cell Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

Multiple myeloma (MM) is a chronically managed blood cancer with a median age of 69 years at the time of diagnosis. Although high dose melphalan and autologous stem cell transplantation (ASCT) remains a standard of care for eligible patients, more than half of the newly diagnosed MM patients are deemed ineligible due to comorbidities or complications of the disease by itself. In this setting, where ASCT is deemed inappropriate, patients could still achieve durable and deep responses if given the appropriate treatment plan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1786558DOI Listing

Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma.

Skeletal Radiol 2020 Jul 3. Epub 2020 Jul 3.

Department of Diagnostic Radiology, Stanford University, Stanford, CA, USA.

Objective: To determine association of body composition measurements on CT and PET with progression of smoldering myeloma to multiple myeloma.

Methods: A retrospective cohort study in 65 patients with smoldering myeloma and PET/CT at diagnosis was performed at a tertiary cancer center. Subjects were between 38 and 87 years of age (mean 64) and included 37 males. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00256-020-03529-2DOI Listing

Impact of CD44 gene single nucleotide polymorphism (rs 13347) in mobilization of autologous HSCT.

Transfus Apher Sci 2020 Jun 27:102869. Epub 2020 Jun 27.

Department of Internal Medicine, Faculty of Medicine, Alexandria University, Egypt.

MOBILIZATION: of stem cells into peripheral blood is a crucial step in the procedure of autologous stem cell transplantation. Mobilization can be affected by many variables;underlying diseases, prior treatment and age. Many genetic polymorphisms mainly in adhesion molecules are thought to affect mobilization success. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2020.102869DOI Listing

Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization.

BMC Cancer 2020 Jul 2;20(1):619. Epub 2020 Jul 2.

Division of Hematology-Oncology, Department of Internal Medicine, Korea University School of Medicine, 73, Goryeodae-ro, Seongbuk-gu, Seoul, 02841, South Korea.

Background: We assessed the mechanism of hematopoietic stem cell (HSC) mobilization using etoposide with granulocyte-colony stimulating factor (G-CSF), and determined how this mechanism differs from that induced by cyclophosphamide with G-CSF or G-CSF alone.

Methods: We compared the clinical features of 173 non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell transplantation (auto-PBSCT). Additionally, we performed in vitro experiments to assess the changes in human bone marrow stromal cells (hBMSCs), which support the HSCs in the bone marrow (BM) niche, following cyclophosphamide or etoposide exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-07102-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330970PMC

DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality.

Blood Adv 2020 Jul;4(13):3024-3033

Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In addition, CAR T-cell-mediated toxicities can involve any organ system, with varied impacts on outcomes, depending on patient factors and involved organs. We performed detailed analysis of organ-specific toxicities and their association with outcomes in 60 patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 CAR T cells by assessing all toxicities in organ-based groups during the first year posttreatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2020001972DOI Listing

Isolated Intracranial Myeloid Sarcoma Mimicking Malignant Lymphoma: A Diagnostic Challenge and Literature Reviews.

Onco Targets Ther 2020 25;13:6085-6092. Epub 2020 Jun 25.

Department of Pathology and Key Laboratories for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University of Medical, Shihezi, 832002, People's Republic of China.

Isolated intracranial myeloid sarcoma (MS) is an unusual variant tumor with few cases reported so far in the medical literature. A 29-year-old woman was admitted to our hospital presenting progressive visual loss in the right eye and weight loss (20 kg) without a previous history of hematological disease (HD). Radiologic evaluation showed the evidence of intracranial mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S245828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323804PMC
June 2020
1.342 Impact Factor

Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.

Cancer Med 2020 Jul 1. Epub 2020 Jul 1.

Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Purpose: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). However, this therapy failed in nearly 25% patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3259DOI Listing

Demyelinating polyneuropathy and lymphoplasmacytic lymphoma coexisting in 36-year-old man: A case report.

World J Clin Cases 2020 Jun;8(12):2566-2573

Department of Internal Medicine, Autoimmune and Metabolic Diseases, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice 40-752, Poland.

Background: Lymphoplasmacytic lymphoma is a rare non-Hodgkin's lymphoma, occurring mostly in the elderly. It develops slowly and leads to malignant proliferation of lymphoid line cells in the bone marrow, lymph nodes and spleen. It may also affect nerve roots and meninges; some patients develop sensorimotor polyneuropathy which may precede general symptoms of lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12998/wjcc.v8.i12.2566DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322434PMC

Primary Pulmonary Diffuse Large B Cell Lymphoma Mimicking Metastasis: A Case Report and Literature Review.

Onco Targets Ther 2020 19;13:5837-5843. Epub 2020 Jun 19.

Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, Jilin, People's Republic of China.

Primary pulmonary diffuse large B cell lymphoma (PPDLBCL) is extremely rare, with fewer than 40 cases reported to date and a lack of systemic analysis. Herein, we present a case of PPDLBCL mimicking metastasis in a heavily treated patient with breast cancer. To our knowledge, this is the first reported case of PPDLBCL in a patient with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S251344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311097PMC

Teaching Neuroimages: Rare skull base involvement in neurosarcoidosis.

Neurology 2020 Jun 30. Epub 2020 Jun 30.

Department of Neurology, The Royal London Hospital, London, UK

A 57-year-old woman was admitted with a tonic-clonic seizure on a background of systemic sarcoidosis with uveitis and hilar lymphadenopathy. She had previously been well and stopped steroids one year before presentation. CT showed a sclerotic lesion with focal lucent areas in the skull base MRI revealed a frontal FLAIR hyperintense oedematous lesion with meningeal enhancement in gadolinium T1 This appearance on imaging evokes broad differential diagnoses such as sarcoidosis, fungal (although she had increasing lesion size despite six-month treatment with amphotericin B), craniofacial fibrous dysplasia, atypical lymphoma, nasopharyngeal carcinoma, myeloma and tuberculosis, therefore necessitating biopsy for definitive evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000010082DOI Listing

Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis.

In Vivo 2020 Jul-Aug;34(4):2095-2100

Division of Respiratory Medicine, JA Toride Medical Center Hospital, Toride, Japan.

Aim: To clarify the correlation between serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA) and metastasis and survival in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients.

Patients And Methods: CEA and CYFRA levels in 131 ALK-rearranged NSCLC patients were determined using fluorescence in situ hybridization (FISH), real time-reverse transcription polymerase chain reaction, and immunohistochemistry, using biopsy specimens, cytology specimens, and plasma specimens. Cut-off value of each marker was determined as 10 ng/ml. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/invivo.12013DOI Listing

A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity.

Clin Lymphoma Myeloma Leuk 2020 May 21. Epub 2020 May 21.

Baskent University Adana Adult Bone Marrow Transplantation Center, Adana, Turkey.

Background: Approximately half of patients with relapsed chemosensitive disease achieve robust responses with BEAM (BCNU, etoposide, cytarabine, and melphalan) and autologous stem cell rescue. The scarcity of comparative studies further limits alternative treatment protocols, such as the MITO/MEL (mitoxantrone, melphalan) protocol.

Patients And Methods: In this retrospective multicenter study, we compared the BEAM and MITO/MEL regimens used before autologous hematopoietic stem cell transplantation (ASCT) in terms of efficacy and side effects in patients with Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2020.05.009DOI Listing

Physical and chemical stability of cytarabine in polypropylene syringes.

J Oncol Pharm Pract 2020 Jun 30:1078155220937405. Epub 2020 Jun 30.

National Center for Bone Marrow Transplantation, Tunis, Tunisia.

Background: Cytarabine is widely used to treat leukemia and lymphoma. Currently, Cyrabol®, powder for injection, is one of the specialties marketed in Tunisia. However, no stability data when diluted with 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155220937405DOI Listing

A Case of Primary Sacral Lymphoma Evaluated by 18F-FDG PET/CT.

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University; and Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, People's Republic of China.

Primary sacral lymphoma is an unusual bone malignant tumor that poses a diagnostic challenge. Herein, we report a rare case of primary sacral lymphoma, which was initially assessed as suspicious bone metastasis. The subsequent histology and immunohistochemistry of the sacral biopsy confirmed the diagnosis of diffuse large B-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003195DOI Listing

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.

Acta Haematol 2020 Jun 30:1-8. Epub 2020 Jun 30.

Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Acute myeloid leukemia (AML) patients not in remission and beyond first or second complete remission are considered allogeneic stem cell transplant (SCT) candidates. We present 361 patients who underwent SCT from matched related or unrelated donors between 2005 and 2013. The purpose was to identify a subgroup of patients with active disease at the time of transplant that benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507012DOI Listing

Bone up on spinal osseous lesions: a case review series.

Insights Imaging 2020 Jun 29;11(1):80. Epub 2020 Jun 29.

Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Spinal osseous neoplasms are frequently encountered and can be challenging when present as solitary lesions. Familiarity with the range of benign and malignant spinal pathology can help the radiologist formulate a comprehensive differential diagnosis. This article focuses on the spectrum of extradural spinal tumors, accounting for the majority of primary spinal tumors, by comparing the epidemiology, pathophysiology, clinical presentation, and characteristic imaging appearance of these lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-020-00883-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324468PMC

A Clinically Applicable Approach to the Classification of B-Cell Non-Hodgkin Lymphomas with Flow Cytometry and Machine Learning.

Cancers (Basel) 2020 Jun 24;12(6). Epub 2020 Jun 24.

Laboratory of Immunopathology, Division of Pathology, A.O. Ordine Mauriziano, 10128 Turin, Italy.

The immunophenotype is a key element to classify B-cell Non-Hodgkin Lymphomas (B-NHL); while it is routinely obtained through immunohistochemistry, the use of flow cytometry (FC) could bear several advantages. However, few FC laboratories can rely on a long-standing practical experience, and the literature in support is still limited; as a result, the use of FC is generally restricted to the analysis of lymphomas with bone marrow or peripheral blood involvement. In this work, we applied machine learning to our database of 1465 B-NHL samples from different sources, building four artificial predictive systems which could classify B-NHL in up to nine of the most common clinico-pathological entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061684DOI Listing

[Molecular diagnosis angioimmunoblastic T-cell lymphoma].

Ter Arkh 2019 Jul 15;91(7):63-69. Epub 2019 Jul 15.

National Research Center for Hematology.

Aim: to determine molecular diagnostics routine for different tissue samples in angioimmunoblastic T-cell lymphoma.

Materials And Methods: Molecular studies were performed for 84 primary AITL patients. The median age was 61 year (29-81); the male to female ratio was 48/36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000330DOI Listing

[The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].

Ter Arkh 2019 Jul 15;91(7):52-62. Epub 2019 Jul 15.

National Research Center for Hematology.

Aim of the issue was to compare clinical characteristics and treatment results of patients with follicular lymphoma (FL) with translocations involving loci of c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes and patients with high - grade B-cell lymphoma [High - grade B-cell lymphoma (HGBL), double - hit (DH)]. Materials and methods. Since 2004 to 2017 years in National Research Center for Hematology 12 patients with high - grade B-cell lymphoma double - hit (HGBL DH) and 6 FL patients with translocations involving c-MYC and BCL2 and/or BCL6 had been treated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000070DOI Listing

[CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study].

Ter Arkh 2019 Jul 15;91(7):35-40. Epub 2019 Jul 15.

National Research Center for Hematology, Department of Intensive High-Dose Chemotherapy with Round-the-Clock and Day Hospital (IVHT with CS and DS).

Aim of the issue was to determine indications for intratecal chemotherapy drugs administration to prevent relapse of diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement.

Materials And Methods: Since January 2009 to December 2018 102 patients with primary nodal DLBCL over 18 years old were treated in the National Research Center for Hematology, Moscow, Russian Federation. Diagnosis were established in all cases according to histological and immunohistochemical studies which made it possible to exclude the transformation of mature B-cell lymphoma into DLBCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.07.000323DOI Listing

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Blood Adv 2020 Jul;4(13):2927-2938

Department of Lymphoma and Myeloma and.

Mantle cell lymphoma (MCL) is an incurable rare subtype of non-Hodgkin lymphoma and is subject to relapse and therapeutic resistance. Molecular aberrations in MCL affect pathogenesis, prognosis, and therapeutic response. In this systematic review, we searched 3 databases and selected 32 articles that described mutations in MCL patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001350DOI Listing

Colonic mucosa-associated lymphoid tissue in a renal transplant recipient: a case report.

J Med Case Rep 2020 Jun 28;14(1):81. Epub 2020 Jun 28.

Department of Nephrology, St Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy, Victoria, 3065, Australia.

Background: Extra-gastric (particularly colonic) lymphoma of mucosa-associated lymphoid tissue in the immunosuppressed solid organ transplant recipient is rare. We report a case of low-volume mucosa-associated lymphoid tissue lymphoma with colonic and bone marrow involvement in a renal transplant recipient that has been managed conservatively.

Case Presentation: A 62-year-old Caucasian man, 14 years after kidney transplantation, was diagnosed as having extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tissue with bone marrow and colonic involvement, after a colonoscopy identified mucosa-associated lymphoid tissue lymphoma in a sessile sigmoid polyp following surveillance fecal occult blood testing that returned a positive result. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-020-02387-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321533PMC

Primary pulmonary extranodal natural killer/T-cell lymphoma (ENKTL), nasal type: Two case reports and literature review.

Medicine (Baltimore) 2020 Jun;99(26):e20822

Department of Cardio-Thoracic Surgery, Shenzhen University General Hospital.

Introduction: Extranodal natural killer/T-cell lymphoma (ENKTL) - nasal type is an aggressive form of malignant non-Hodgkin lymphoma with a very poor prognosis. Especially primary pulmonary ENKTL is a relatively rare form of non-Hodgkin lymphoma. Until now, the prevalence of primary pulmonary ENKTL is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020822DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328944PMC

Chimeric Antigen Receptors for the Tumour Microenvironment.

Adv Exp Med Biol 2020 ;1263:117-143

Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.

Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-44518-8_8DOI Listing

Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.

Int J Clin Pract 2020 Jun 24:e13594. Epub 2020 Jun 24.

Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia.

Background: About 20% to 30% of diffuse large B-cell lymphoma (DLBCL) patients experience early disease progression despite R-CHOP chemotherapy treatment. Revised-international-prognostic-index-score could risk stratify DLBCL patients but does not identify exactly which patient will be resistant to R-CHOP therapy or experience early relapse.

Aims Of The Study: To analyse pre-treatment clinical features of DLBCL patients that are predictive of R-CHOP therapy resistance and early disease relapse after R-CHOP therapy treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijcp.13594DOI Listing

Rare Case of Diffuse Large B-Cell Lymphoma Mimicking Acute Monocytic Leukemia, Associated with Complex Karyotype.

Ann Clin Lab Sci 2020 May;50(3):397-400

Department of Clinical Laboratory, Affiliated Hospital of Engineering University of Hebei, Handan, Hebei Province, China.

Objective: Diffuse Large B-Cell Lymphoma (DLBCL), NOS, constitutes 25-35% of adult non-Hodgkin lymphomas in developed countries, and a higher percentage in developing countries; older people are prone to the disease. Three frequent morphological variants have been recognized, including centroblastic, immunoblastic, and anaplastic variants. However, there are still other rare morphological variants of DLBCL, presenting challenge in diagnosis and treatment. Read More

View Article

Download full-text PDF

Source

Diaphanous-related formin mDia2 regulates beta2 integrins to control hematopoietic stem and progenitor cell engraftment.

Nat Commun 2020 Jun 23;11(1):3172. Epub 2020 Jun 23.

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA.

Bone marrow engraftment of the hematopoietic stem and progenitor cells (HSPCs) involves homing to the vasculatures and lodgment to their niches. How HSPCs transmigrate from the vasculature to the niches is unclear. Here, we show that loss of diaphanous-related formin mDia2 leads to impaired engraftment of long-term hematopoietic stem cells and loss of competitive HSPC repopulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-16911-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311390PMC
June 2020
10.742 Impact Factor

TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.

Blood Adv 2020 Jun;4(12):2821-2836

Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom; and.

Waldenström macroglobulinemia (WM) is a rare malignancy in which clonal B cells infiltrate the bone marrow and give rise to a smaller compartment of neoplastic plasma cells that secrete monoclonal immunoglobulin M paraprotein. Recent studies into underlying mutations in WM have enabled a much greater insight into the pathogenesis of this lymphoma. However, there is considerably less characterization of the way in which WM B cells differentiate and how they respond to immune stimuli. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2019001279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322944PMC

LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.

Eur Rev Med Pharmacol Sci 2020 Jun;24(11):5933-5945

Department of Orthopedic Surgery Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Objective: Osteosarcoma (OS) is a common primary bone tumor. Despite multiple treatment strategies have made great progress, the overall clinical outcome of OS patients is frustrating. Long non-coding RNA (lncRNA) LINC00467 has been reported in several cancers, while the research of the role of LINC00467 in OS is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_202006_21486DOI Listing

Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols.

Cancers (Basel) 2020 Jun 18;12(6). Epub 2020 Jun 18.

AYA Oncology and Pediatric Radiotherapy Unit, CRO-Centro di Riferimento Oncologico di Aviano, IRCCS, 33081 Aviano, Italy.

Adolescents and young adults (AYAs) represent a distinct group of patients. The objectives of this study were: To compare adolescent prognosis to that of younger children; to compare the results achieved with the two consecutive protocols in both age groups; to analyze clinical characteristics of children and adolescents. Between 1996 and 2017, 1759 patients aged <18 years were evaluable for the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12061620DOI Listing

[Coexistence of mycosis fungoides and essential thrombocythemia with JAK2V617F].

Rev Med Inst Mex Seguro Soc 2019 Sep 2;57(5):329-333. Epub 2019 Sep 2.

Instituto Mexicano del Seguro Social, Hospital General Regional No. 251, Departamento de Hematología. Metepec, Estado de México, México.

Background: The coexistence of myeloproliferative neoplasms (MPNs), specifically essential thrombocythemia and lymphoproliferative neoplasms, are a very rare finding with a frequency < 1%.

Case Report: We present the case of a woman with diagnosis of mycosis fungoides early stage IB, of 5 months of evolution, she received systemic treatment based on methotrexate orally for 4 months; after this, she started with important thrombocythemia reaching up to 1 200 000/mm3 platelets and leukocytosis ranging from 10 000 - 13000/mL. A study protocol for chronic myeloproliferative disease was performed, reporting 90% cellular bone biopsy, erythroid myeloid ratio 5:1, 25 megakaryocytes per mm3, some with hyperlobed nuclei, and giant nuclei. Read More

View Article

Download full-text PDF

Source
September 2019